The heredERA BC study is aiming to address this challenge through optimizing the targeting of disease biology, by evaluating the efficacy and safety of SoC HER2-targeted therapy (PH FDC SC) combined with the next-generation oral SERD giredestrant, in patients with HER2+, ER+ mBC treated in the 1L setting. This evidence concerns the gene ERBB2 and breast cancer.